Latest: FDA Approves New Biosimilar for Oncology Treatment

On the Path to Greater Precision in Treating Multiple Myeloma

Past efforts to collect data and to understand the relationship between minimal residual disease and outcomes will allow help researchers in multiple myeloma develop a new generation of targeted therapies, decide when treatment can be stopped, and possibly screen populations for the disease.
Tags:
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago